Myeloid Antigen Expression in Childhood Acute Lymphoblastic Leukemia and Its Relevance for Clinical Outcome in Indonesian ALL-2006 Protocol by Supriyadi, E. et al.
Hindawi Publishing Corporation
Journal of Oncology
Volume 2012, Article ID 135186, 7 pages
doi:10.1155/2012/135186
Research Article
Myeloid Antigen Expression in Childhood Acute Lymphoblastic
Leukemia and Its Relevance for Clinical Outcome in Indonesian
ALL-2006 Protocol
Eddy Supriyadi,1 Anjo J. P. Veerman,1, 2 Sutaryo,1 Ignatius Purwanto,1
Peter M. vd Ven,3 and Jacqueline Cloos2, 4
1 Pediatric Hematology Oncology Division, Department of Pediatrics, Dr. Sardjito Hospital, Faculty of Medicine,
Universitas Gadjah Mada, Jl. Kesehatan No. 1, Yogyakarta 55281, Indonesia
2 Pediatric Oncology/Hematology Division, Department of Pediatrics, VU University Medical Center, 1007 MB Amsterdam,
The Netherlands
3 Department of Epidemiology and Biostatistics, VU University Medical Center, 1007 MB Amsterdam, The Netherlands
4 Department of Hematology, VU University Medical Center, 1007 MB Amsterdam, The Netherlands
Correspondence should be addressed to Eddy Supriyadi, e.supriyadi@gadjahmada.edu
Received 12 May 2012; Accepted 15 September 2012
Academic Editor: Gertjan Kaspers
Copyright © 2012 Eddy Supriyadi et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The frequency of acute lymphoblastic leukemia (ALL) patients expressing myeloid antigens on their ALL cells varies between
5 and 36% in several diﬀerent studies. The clinical relevance of myeloid antigen expression in childhood ALL is controversial.
In Indonesian patients, no data were present. Therefore, in Yogyakarta, Indonesia, we analyzed 239 ALL patients who were
immunophenotyped including myeloid markers (CD13, CD33, CD117, and/or cMPO). Myeloid antigen expression was found in
25% of patients. Expression of myeloid antigen in B-lineage leukemia was 27%, and in T-lineage leukemia, it was 18% (P = 0.15).
No association was found between myeloid antigen expression and clinical or biological features. In the whole cohort of patients
we did not find a significant association between myeloid antigen expression and survival, although leukemia-free survival at 3
years was higher in the myeloid-negative patients (73%± 6%) compared to myeloid-positive patients (67%± 8%). Interestingly,
in T-ALL patients, expression of myeloid antigens was an independent adverse prognostic factor (hazard ratio: 3.26, 95% CI:
1.06–9.98, P = 0.04). Kaplan-Meier analysis for event-free survival was also significant (log rank P = 0.03) in this subgroup. In
conclusion, in the Indonesian ALL population, in particular, myeloid antigen-expressing T-ALL patients had a higher chance of
having induction failure.
1. Introduction
Acute leukemia is a clonal expansion of malignant cells in
bone marrow, blood, and other organs. The acute leukemias
are classified into acute myeloblastic leukemia (AML) and
acute lymphoblastic leukemia (ALL) based on lineage of the
blast cells [1–3]. The proliferating lymphoid progenitor cells,
arrested in various stages of maturation, can be identified
as B-, T-, or mixed-lineage leukemia [4–7]. In childhood
ALL, immunophenotyping showed that in B- and T-lineage
ALL additional antigens can be expressed that are normally
associated with myeloid lineages, that is, CD11b, 13, 14,
15, 33, 36, 65, or 117. In various childhood ALL studies,
a large variation is reported on expression of myeloid
markers ranging from 5 to 36% of cases [5, 8–15]. Moreover,
the clinical relevance of myeloid antigen expression in
childhood ALL as a prognostic factor remains controversial
[5, 8–12].
Myeloid-positive ALL either originates from progenitor
cells, which had not diﬀerentiated into either myeloid or
lymphoid cells (lineage promiscuity), or from progenitor
cells, which have both myeloid and lymphoid features (lin-
eage infidelity) [16, 17]. Some studies showed that children
with myeloid-positive ALL had a poorer clinical outcome
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Table 1: Various results of myeloid antigen expression in childhood ALL.
Author, year No. of cases Myeloid+ (%) Myeloid antigens used Reference
Pui et al., 1990 372 6.4 CD11b, 13, 14, 15, 33, 36 [11]
Pui et al., 1991 410 6.1∗ CD11b, 13, 14, 15, 33, 36 [12]
Wiersma et al., 1991 236 23 CD13, 33, 14 [10]
Kurec et al., 1991 51 16 CD13, 14, 15, 33 [18]
Ludwig et al., 1994 736 7 CD13, 33, 65 [13]
Reiter et al., 1994 975 5 CD13, 33, 65 [14]
Uckun et al., 1997 1557 16.7 CD13, 33 [5]
Putti et al., 1998 908 32 CD11b, 13, 14, 15, 33, 65w [8]
Den Boer et al., 1999 167 36 CD13, 33 [9]
Ng et al., 2000 166 23 CD13, 33 [15]
This study 239 25 CD13, 33, 117, MPO
∗Myeloid+ ALL only if the leukemic cells coexpressed two or more myeloid-associated antigens; Myeloid+: myeloid-associated antigen expression; CD: cluster
of diﬀerentiation; cMPO: cytoplasmic myeloperoxidase.
compared with those of myeloid-negative ALL patients [10,
18, 19]. In contrast, other studies could not confirm this
result [5, 8, 11, 12]. The discrepancies between studies may
be related to the use of diﬀerent treatment protocols [20],
diﬀerent populations, as well as diﬀerent definition criteria
of myeloid-positive ALL, which are summarized in Table 1.
In this study, the myeloid antigen presenting features of the
Indonesian ALL population is determined. In addition, the
relevance of myeloid antigen expression on both B-lineage
and T-lineage ALL patients for treatment outcome was also
analyzed.
2. Materials and Methods
From March 2006 to December 2011, 268 pediatric patients
aged <15 years with newly diagnosed ALL were admitted
to Dr. Sardjito Hospital, Yogyakarta, Indonesia (DSH).
Inclusion criteria for this study are 0–14 completed years of
age, no prior treatment, and treated with Indonesia 2006
ALL protocol. Exclusion criteria are prior treatment and
mature B-ALL. Among these children, 239 cases fulfilled the
inclusion criteria and had complete data available for both
clinical parameters and immunophenotyping, including
evaluation of myeloid antigen expression.
2.1. Morphologic Diagnosis. Morphologic diagnosis was
based on French-American-British (FAB) criteria. Bone
marrow (BM) and peripheral blood (PB) smears were
stained using May Gru¨nwald-Giemsa, Periodic Acid-Schiﬀ,
Sudan Black, and myeloperoxidase.
2.2. Immunophenotyping. BM cells were also tested on 3
colors Becton Dickinson FACSCalibur flowcytometer (BD
FACSCalibur) for immunophenotyping. The panel of mon-
oclonal antibodies was CD2, cytoplasmic (c)CD3, CD7 for
precursor T-ALL, CD10, CD19, CD22, cCD79a for precursor
B-ALL, CD13, CD33, cMPO, and CD117 formyeloid lineage,
and CD45, IgG1, IgM, Tdt, and CD34 for non lineage
[3, 21]. For membrane staining monoclonal antibodies were
added (IgG1, CD2, CD7, CD10, CD13, CD19, CD22, CD33,
CD34, CD117, and CD45) to 30 µL of cell suspension
in separate polystyrene tubes. This suspension was then
incubated in the dark for 15 minutes at room temperature.
After incubation, 16.6 µL paraformaldehyde (4%) was added
to the cell suspensions and incubated for 4 minutes at
room temperature, in the dark. Then, 1mL Lysing Solution
was added and lysed 10 minutes at room temperature,
in the dark. Cells were then centrifuged 1500 rpm for 5
minutes, cell pellets was washed twice, and resuspended in
300–500 µL PBS. For Cytoplasmic staining (cIgG1, cCD79a,
cCD3, cMPO, and cTdT) cell suspensions were incubated
for 15 minutes at room temperature and then washed
twice and resuspended 300–500 µL of PBS, run in the BD
FACSCalibur. Patients in this study were classified of having
myeloid antigen expression (myeloid-positive) if B-lineage
or T-lineage ALL cells were expressing one or more of
the myeloid antigens CD13, CD33, CD117, and/or cMPO.
When a sample was positive for more than one lineage, we
used a scoring system adapted from The European Group
for the Immunological Classification of Leukemias (EGILs).
According to this scoring system, a case is considered
biphenotypic when point values are greater than two for the
myeloid and one for the lymphoid lineages.
2.3. Treatment Protocol. The Indonesia 2006 ALL Pro-
tocol has a 4-drug treatment in induction phase: Cor-
ticosteroid (Prednisone/Dexamethasone), Vincristine, L-
Asparaginase and Anthracycline. Consolidation phase:
Cyclophosphamide, Methotrexate (MTX) intrathecally (i.t.)
High Dose MTX, and 6-Mercaptopurine (6-MP). Main-
tenance phase: 6-MP, MTX, and pulses of Vincristine,
Dexamethasone/Prednisone and MTX i.t.
2.4. Statistical Analysis. Myeloid antigen expression was
dichotomized, and the threshold was set at 20%. Association
between myeloid antigen expression and clinical and biolog-
ical variables was tested for using Chi-square test or Fisher’s
exact test where appropriate. The clinical and biological vari-
ables considered were age category, white blood cell count
(WBC) at diagnosis, FAB subtype, risk classification, and
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Table 2: Myeloid antigen expression in childhood acute lymphoblastic leukemia in Yogyakarta, Indonesia.
Variable
Patients (%)
n = 239
Myeloid positive
n (%)
Myeloid negative
n (%)
P value
60 (25) 179 (75)
Sex
Male 139 (58) 37 (27) 102 (73)
0.52
Female 100 (42) 23 (23) 77 (77)
Age
1–9 years 188 (79) 49 (26) 139 (74)
0.51
<1 & 10–14 yrs 51 (21) 11 (22) 40 (78)
White blood cell count
<50.000/mm3 185 (77) 47 (25) 138 (75)
0.84
>50.000/mm3 54 (23) 13 (24) 41 (76)
French-American-British classification
ALL-L1 198 (83) 44 (22) 154 (78)
0.02
ALL-L2 41 (17) 16 (39) 25 (61)
Immunophenotyping
B-lineage 183 (77) 50 (27) 133 (73)
0.15
T-lineage 56 (23) 10 (18) 46 (82)
Risk classification (NCI based)
Standard risk 95 (40) 29 (31) 66 (69)
0.17
High risk 144 (60) 31 (22) 113 (79)
immunophenotype. Survival curves for event-free survival
and leukemia-free survival were computed using Kaplan-
Meier analysis, and curves for groups based on myeloid
antigen expression were compared with the log-rank test.
Survival analyses were performed for the overall group and
also separately for the B-ALL and T-ALL group. Hazard
ratios for myeloid antigen expression and other variables of
interest were computed using Cox regression. Because all
patients in high-risk group were given dexamethasone while
patients in the standard risk group were randomized for
prednisone-dexamethasone, hazard ratios were calculated
with correction to the protocol used. Event-free survival
(EFS) was calculated from date of start treatment to date
of first event: induction failure, death, resistant disease, or
relapse. Leukemia-free survival (LFS) was calculated from
date of start treatment to date of a leukemic event: induction
failure or relapse. No complete remission or induction failure
was determined at the end of induction treatment and
defined as there were lymphoblasts in peripheral blood or
cerebrospinal fluid and/or more than 5% lymphoblasts in
the bone marrow. A two-sided P value less than 0.05 was
used as level for statistical significance. SPSS version 15 was
used to analyze the data. Multivariate analyses were restricted
to those risk factors that had a P-value of less than 0.20
in a univariate analysis. As the variable risk classification
was determined on the basis of WBC and age, we excluded
this variable from multivariate analyses when both age and
WBC were already included in the multivariate analyses. For
analysis on the total ALL group, and the B-Lineage ALL
group a variable denoting the protocol used was included in
all models.
3. Results
Two hundred and sixty-eight patients were immunophe-
notyped. Twenty-nine patients were excluded (12 patients
used Wijaya Kusuma-2000 protocol, 5 had treatment before,
4 refused treatment, 3 patients were inconclusive, 4 got
suboptimal treatment, and 1 patient was aged more than
14 years). Two hundred and thirty-nine patients met the
inclusion criteria and were analyzed for clinical and biolog-
ical features. These data are summarized in Table 2. Since
one of the national cancer institute criteria for standard risk
classification is a child over 1 year old and under 10 years old,
age was grouped as 1–9 years and <1 plus >10 years.
We analyzed the immunophenotype of these ALL by a
three-color flow cytometer and determined the immunologic
classification into B or T-phenotypes. For B-ALL, the most
frequent markers were CD19, CD10, cytoplasmic CD79a,
and CD22. For T-ALL and the most frequent markers were
CD7, cytoplasmic CD3 and CD2. The Immunophenotypic
profiles of childhood ALL in Yogyakarta are presented in
Table 3.
3.1. Overall Patients. In the whole patient group, myeloid
antigen was expressed in 60 (25%) of 239 patients tested.
Majority of patients with morphology ALL-L1 had no
myeloid antigen expression (P = 0.02). In univariate analysis
for EFS, ages at diagnosis and risk group were found to
be statistically significant predictors for event-free survival.
Multivariate analysis showed that age category was the
only factor significant, HR 2.00 (95%CI: 1.23–3.23, P =
0.006). Kaplan-Meier analysis of EFS showed no diﬀerence
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Table 3: Immunophenotypic profiles of childhood ALL in
Yogyakarta, Indonesia.
Marker
B-lineage T-Lineage
% %
CD2 5 76
CD3 25 80
CD7 8 91
CD10 82 35
CD19 93 14
CD22 71 9
CD79a 80 10
CD34 56 22
TdT 62 43
CD33 10 12
CD13 21 22
CD117 4 7
MPO 0 4
for myeloid antigen expression (Figure 1(a)). There was
nothing significant in univariate analysis for LFS. Kaplan-
Meier analysis showed that LFS at 4 years was 80% ± 5% in
the myeloid-negative group compared to 67% ± 8% in the
myeloid-positive group (Figure 1(b)).
The proportion of myeloid antigen expression in the
B-lineage group was 27%, while 10 out of 56 patients
(18%) were in T-ALL group (P = 0.15). Moreover, the
groups did not diﬀer in relevant clinical and biological
features (Table 4). Since both groups have a distinct clinical
prognosis, we also stratified the data for the diﬀerent
lineages.
3.2. Precursor B-ALL Patients. Univariate analyses for EFS
showed that sex, age at diagnosis, and risk classification
were significant factors. On multivariate analysis (correcting
for protocol used), nothing remained significant. For LFS,
there was no factor significant in univariate analysis. We did
not perform multivariate analyses since there were no other
variables that had a P value smaller than 0.2.
In the Kaplan-Meier analysis for EFS, precursor B-ALL
patients with and without myeloid antigen expression had
a similar prognosis. EFS at 4 years for myeloid-positive B-
lineage ALL was 53% ± 8%, and for myeloid-negative it
was 55% ± 6%, P = 0.621 (Figure 2(a)). Kaplan-Meier
analysis for LFS also showed no association of survival with
myeloid antigen expression (LFS at 4 years was 73% ± 6%
for myeloid-negative versus 70% ± 9% for myeloid positive,
P = 0.420, Figure 2(b)).
3.3. T-ALL Patients. Univariate analysis for EFS showed
no statistically significant parameters except for myeloid
antigen expression. Including the known common factors
influencing survival, we did perform multivariate analysis
and found that expression was an independent risk factor for
EFS (HR: 3.26 (1.06–9.98), P = 0.04). Kaplan-Meier analysis
for EFS (Figure 3(b)) showed that myeloid-positive patients
had a worse prognosis. Survival at 4 years for myeloid
negative was 58% ± 15% while for myeloid positive was
36% ± 19% (log rank P = 0.03). LFS analysis showed that
myeloid-positive patients had a worse prognosis. Survival
at 4 years for myeloid negative was 77% ± 17% while for
myeloid positive was 52% ± 23% (log rank P = 0.001). Of
the events considered, induction failure was more common
in myeloid-positive than in myeloid-negative patients. In
myeloid-positive patients, 2 out of 10 patients had this event,
while in myeloid-negative patients, no patient had induction
failure, Fisher’s exact test, P = 0.029.
4. Discussion
Leukemic blast cells generally demonstrate lineage fidelity
and therefore are believed to reflect stages of normal diﬀer-
entiation of B- or T-lineage [22, 23]. Recent improvement
on immunophenotyping makes it possible to detect mixed
antigen expression in one cell, including myeloid antigen
expression in ALL [10]. The clinical significance of myeloid
antigen coexpression has remained controversial [5, 8–15].
We studied the clinical significance of myeloid antigen
expression and the treatment outcome in 239 Indonesian
children with ALL. The ALL patients analyzed here were
classified as having myeloid antigen coexpression according
to the expression of at least one of these 4 markers: CD13,
CD33, CD117, and cMPO. The 25% incidence of myeloid
antigen expression in this Indonesian population was slightly
higher compared to what was found in Malaysia by Ng et al.
(2000), who reported 23% [15], but lower compared to Den
Boer et al. (1999) who found 36% in a European population
[9] (Table 1). The variation of those findings may be due
to variations in definition; some authors define myeloid
positive as two or more myeloid antigens positive, or 1 or
more as in this study. In addition, there is variation in the
number of monoclonal antibodies used and which varies
from only 2 monoclonal antibodies [5, 9, 15] to as many as
6 [8, 11, 12]. Besides these more technical explanations, the
myeloid antigen expression may also diﬀer due to ethnical
diﬀerences.
A study in a single institution conducted by Wiersma
et al. (1991) reported a 3-year EFS of 84% for myeloid-
negative ALL with WBC < 50.000/mm3 compared to
57% for myeloid-positive ALL. For samples with WBC >
50,000/mm3, they reported 47% 3-year EFS for myeloid-
negative ALL compared to 26% for myeloid-positive ALL.
Multivariate analysis showed that myeloid antigen expression
was the most important predictor for a poor EFS [10]. This
result was similar with the study of Kurec et al. (1991) [18].
In a more recent study, patients with mixed phenotypic
acute leukemia (MPAL) especially in B-lineage leukemia with
myeloid antigen expression had a lower EFS rate than those
with nonmixed acute leukemia [24]. These results were also
consistent with the finding that myeloid-negative patients
had a higher sensitivity to glucocorticoids than myeloid-
positive positive cases, causing a better prognosis in myeloid-
negative ALL. This may be related to diﬀerences in cellu-
lar drug resistance. Leukemic cells from myeloid-positive
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Table 4: Myeloid expression in B-lineage and T-lineage ALL in Yogyakarta, Indonesia.
Variable
B-lineage ALL, n = 183 T-Lineage ALL, n = 56
n (%)
My+
n (%)
P n (%)
My+
n (%)
P
Sex
Male 105 (57) 30 (27)
0.66
34 (61) 7 (21)
0.51
Female 78 (43) 20 (26) 22 (39) 3 (14)
Age
1–9 years 145 (80) 41 (28)
0.57
43 (79) 8 (19)
0.79
<1 & 10–14 yrs 38 (20) 9 (24) 13 (21) 2 (15)
White blood cell count
<50.000/mm3 149 (81) 41 (28)
0.90
36 (64) 6 (17)
0.76
>50.000/mm3 34 (19) 9 (27) 20 (36) 4 (20)
French-American-British classification
ALL-L1 149 (82) 37 (25)
0.11
49 (88) 7 (14)
0.07
ALL-L2 34 (18) 13 (38) 7 (12) 3 (43)
Risk classification (NCI based)
Standard risk 95 (52) 29 (31)
0.31
0 0
—
High risk 88 (48) 21 (24) 56 (100) 10 (18)
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Figure 1: Survival analysis of myeloid expression in overall childhood ALL, treated with Indonesia 2006 protocol. (a) Event-free survival
with log rank P = 0.228 and (b) Leukemia-free survival with log rank P = 0.085.
ALL patients were more resistant to glucocorticoid-induced
killing than cells from myeloid-negative ALL patients [25].
In our study, only in T-ALL patients, myeloid antigen
expression was found to be a significant adverse prognostic
factor (P = 0.04). It has to be emphasized that only a
small number of patients were studied in the T-ALL group.
However, LFS analyses also showed a worse prognosis for
myeloid-positive patients; LFS at 4 years was 52%, while
for myeloid-negative patients, LFS at 3 years was 96%
(P = 0.001). Although our and many other studies have
shown a poor result for myeloid antigen expression in
childhood ALL, other investigators found conflicting results.
Mirro et al [26] and Pui et al. [11] found that myeloid
antigen expression in ALL was not correlated with clinical
outcome. Another study conducted by Putti et al., who
used six diﬀerent myeloid antigens, showed that myeloid-
positive ALL was not associated with immunophenotype and
response to therapy and had no prognostic value [8]. Ng et al.
(2000) found that patients with myeloid antigen expression
were not significantly diﬀerent in presenting features and
treatment outcome compared to those who had no myeloid
antigen expression similar results in B-lineage ALL [15]. It
is conceivable that myeloid antigen expression in ALL loses
its significance when results of treatment get better, as in
many western protocols where EFS reaches levels of 80–
90%.
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Figure 2: Survival analysis of myeloid expression in B-lineage ALL, treated with Indonesia 2006 protocol. (a) Event-free survival with log
rank P = 0.621 and (b) Leukemia-free survival with log rank P = 0.420.
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Figure 3: Survival analysis of myeloid expression in T-lineage ALL, treated with Indonesia 2006 protocol. (a) Event free survival with log
rank P = 0.028 (b) Leukemia free survival with log rank P = 0.001.
In B-lineage ALL, there was no association between
myeloid antigen expression and treatment outcome. In
terms of LFS, however, our results showed that myeloid-
negative B-lineage ALL had a slightly better LFS although
not statistically significant. In multivariate analysis, myeloid
antigen expression was not found prognostically relevant
for LFS in B-lineage ALL. In T-lineage ALL, however, cases
with myeloid antigen expression had a worse prognosis. In
myeloid-negative T-ALL patients (n = 46), there was only 1
relapse in the first year of treatment. Hence, therapy for this
group should be less intense to prevent toxic deaths.
Factors involved in prognosis are also dependent upon
the therapy protocol used. Diﬀerences in protocol can
modify the eﬀect of prognostic factors. Indeed, theoretically,
all prognostic factors lose their eﬀect if the cure rate reaches
100%. In St. Jude, cure rates over 90% are achieved. It is
therefore understandable that the prognostic value of any
marker, including antigen expression, will be most obvious
in situation with lower EFS and LFS, which is the case
in Indonesia. In our setting, treatment was more toxic
compared to other developing countries but less intensive
than in trials in high-income countries. For this reason, our
treatments resulted in inadequate control of the disease. For
myeloid-positive T-ALL, a more intensive protocol should
be implemented, but only in combination with a better
supportive care.
In summary, myeloid antigen expression is common and
occurs in 25% of Indonesian children with ALL. In T-ALL
patients, myeloid antigen expression was associated with a
significantly worse prognosis. It may need more intensive
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(re)induction protocol. T-ALL patients who did not express
myeloid antigens had an excellent leukemia-free survival
(only 1 relapse at 3 years and another late relapse). LFS
at 3 years was 96%; myeloid-negative T-ALL patients could
maybe even do with less intensive treatment.
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